Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $3.17 in the prior trading day, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $3.12, down -1.58%. In other words, the price has decreased by -$1.58 from its previous closing price. On the day, 1.48 million shares were traded. ABUS stock price reached its highest trading level at $3.135 during the session, while it also had its lowest trading level at $3.0.
Ratios:
Our goal is to gain a better understanding of ABUS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.15 and its Current Ratio is at 8.15. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 31 ’25 when Sofia Michael J. bought 250,000 shares for $3.50 per share.
Sofia Michael J. bought 250,000 shares of ABUS for $820,000 on Mar 24 ’25. On Mar 19 ’25, another insider, Sofia Michael J., who serves as the Officer of the company, bought 150,000 shares for $3.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 603142784 and an Enterprise Value of 501976000. For the stock, the TTM Price-to-Sale (P/S) ratio is 96.83 while its Price-to-Book (P/B) ratio in mrq is 6.09. Its current Enterprise Value per Revenue stands at 81.344 whereas that against EBITDA is -6.942.
Stock Price History:
The Beta on a monthly basis for ABUS is 1.52, which has changed by 0.07216489 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $2.63. The 50-Day Moving Average of the stock is -6.30%, while the 200-Day Moving Average is calculated to be -13.23%.
Shares Statistics:
The stock has traded on average 970.74K shares per day over the past 3-months and 1606970 shares per day over the last 10 days, according to various share statistics. A total of 189.96M shares are outstanding, with a floating share count of 148.63M. Insiders hold about 22.38% of the company’s shares, while institutions hold 54.39% stake in the company. Shares short for ABUS as of 1741910400 were 9574515 with a Short Ratio of 10.14, compared to 1739491200 on 7212196. Therefore, it implies a Short% of Shares Outstanding of 9574515 and a Short% of Float of 6.39.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
